From a clinically oriented perspective, the findings that chemokines may also polarize Tregs (so far our data shows relevance only for FOXP3-negative Tregs) opens the window of opportunities for using stabilized chemokines for therapy of inflammatory autoimmunity and GVHD, and also for cancer diseases. The gene discussed is FOXP3; the disease is graft versus host disease.